我要投票 九州通在减肥药行业中的票数:8
· 外 推 电 报 ·
2024-11-21 20:07:13 星期四

【九州通是哪个国家的品牌?】

九州通是什么牌子?「九州通」是 九州通医药集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘宝林在2000期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

九州通医药集团股份有限公司是一家以药品、医疗器械、生物制品、保健品等产品批发、零售连锁、药品生产与研发及有关增值服务为核心业务的大型企业集团。

截至2012年12月31日,九州通医药集团拥有总资产148.04亿元,员工9,148人,下属公司80余家,直营和加盟的零售连锁药店875家。2012年,九州通医药集团实现营业收入295.08亿元,上缴税收近5亿元。

九州通医药集团拥有完善的品种结构和丰富的客户资源,经营品规达160,000多个,上游供货商5,600家,下游客户70,000多家,取得了国内131种药品的全国或区域总经销或总代理资格。至今为止,九州通医药集团已在全国22个省会城市设立了22家省级子公司(大型医药物流中心)、在29个地级市设立了29家地级公司(地区医药物流配送中心)及400多个终端配送点,形成了覆盖全国大部分县级行政区域的物流配送网络。

打造企业核心竞争力,九州通医药集团秉持“技术让服务更卓越”的理念,致力于现代物流技术和信息技术的开发和应用。目前,九州通医药集团是国内唯一具备独立整合物流规划、物流实施、系统集成能力的医药分销企业,并取得了20多项自主知识产权,在现代物流技术和信息技术方面处于国内领先、国际一流的地位,是国内医药行业唯一获得“中国物流改革开放30年旗帜企业”称号的企业。

九州通医药集团具备向上下游客户提供需求解决方案及增值服务的能力,并逐渐将技术增值服务延伸到了上下游产业链,形成了独具特色的物流管理、供应链管理、医院管理三大产品线,可以满足客户对技术的最高要求。

近年来,九州通医药集团曾获得“国家5A级物流企业”、“湖北省最具影响力民营企业”、“湖北省守合同重信用企业”、“中国社会责任感优秀企业”、“全国非公有制企业双强百佳党组织”等多项荣誉。

未来,九州通医药集团将顺应医药市场变革,继续坚持以医药分销为核心业务,以医院纯销、中药材、医疗器械、零售连锁为战略业务,以物流技术营销、电子商务、国际贸易、原料药等为新兴业务的业务组合战略;扩大和完善医药营销网络布局,不断为医药健康产业提供高性价比服务,努力将九州通打造成为中国医药健康产业最佳服务商。

英文翻译:JIUZHOUTONG Pharmaceutical Group Co., Ltd. is a large-scale enterprise group with the core business of wholesale, retail chain, drug production and R & D and related value-added services of drugs, medical devices, biological products, health products and other products. As of December 31, 2012, JIUZHOUTONG Pharmaceutical Group has a total assets of 14.804 billion yuan, 9148 employees, more than 80 subordinate companies, 875 retail chain drugstores directly operated and joined. In 2012, JIUZHOUTONG Pharmaceutical Group achieved an operating revenue of 29.508 billion yuan and turned in tax revenue of nearly 500 million yuan. JIUZHOUTONG Pharmaceutical Group has a complete variety structure and rich customer resources. It operates more than 160000 products, 5600 upstream suppliers and 70000 downstream customers. It has obtained the qualification of national or regional general distribution or general agent of 131 kinds of drugs in China. So far, JIUZHOUTONG Pharmaceutical Group has set up 22 provincial subsidiaries (large pharmaceutical logistics centers) in 22 provincial capitals, 29 prefecture level companies (regional pharmaceutical logistics distribution centers) and more than 400 terminal distribution points in 29 prefecture level cities, forming a logistics distribution network covering most county-level administrative regions of the country. To build the core competitiveness of the enterprise, JIUZHOUTONG Pharmaceutical Group adheres to the concept of "technology makes service more excellent", and is committed to the development and application of modern logistics technology and information technology. At present, JIUZHOUTONG Pharmaceutical Group is the only pharmaceutical distribution enterprise in China that has the ability to independently integrate logistics planning, logistics implementation and system integration, and has obtained more than 20 independent intellectual property rights. It is in the leading position in modern logistics technology and information technology in China and the first-class position in the world. It is the only one in the domestic pharmaceutical industry that has won the title of "30 years banner enterprise of China's logistics reform and opening up" Enterprises. JIUZHOUTONG Pharmaceutical Group has the ability to provide demand solutions and value-added services to upstream and downstream customers, and gradually extends technology value-added services to the upstream and downstream industrial chains, forming a unique logistics management, supply chain management, hospital management three product lines, which can meet the highest requirements of customers for technology. In recent years, JIUZHOUTONG Pharmaceutical Group has won many honors, such as "national 5A level logistics enterprise", "the most influential private enterprise in Hubei Province", "Hubei Province contract abiding and trustworthy enterprise", "China's outstanding enterprise of social responsibility", "national top 100 Party organizations of non-public enterprises". In the future, JIUZHOUTONG Pharmaceutical Group will continue to adhere to the core business of pharmaceutical distribution, the strategic business of hospital pure sales, Chinese herbal medicine, medical devices, retail chain, the business combination strategy of logistics technology marketing, e-commerce, international trade, API and other emerging businesses, expand and improve the layout of pharmaceutical marketing network, and continue to serve the medical health The industry provides cost-effective services and strives to build Jiuzhoutong into the best service provider in China's pharmaceutical and health industry.

本文链接: https://www.waitui.com/brand/02808d9a5.html 联系电话:027*****3017 立即查看

千城特选小程序码

7×24h 快讯

拼多多:第三季度营收增速环比下降,将坚定高质量发展战略应对竞争挑战

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多营收达到994亿元,与上个季度相比,营收的增速有所放缓。业内分析认为,一方面是因为电商行业的竞争依然激烈,另一方面是平台的“百亿减免”等举措影响了短期的财报表现。“为了应对行业竞争,我们将坚定地执行高质量发展战略,继续实行‘减免+扶持’的举措,持续完善平台及产业生态,为供需两侧带来更大的普惠。”拼多多陈磊表示。

7分钟前

拼多多:第三季度利润环比下降22%,将长期投入“新质供给”“电商西进”战略

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多利润达到250亿元,环比下降22%。过去这个季度,拼多多先后推出“百亿减免”“电商西进”“新质商家扶持计划”等重磅举措,持续扩大对生态建设的投资,一定程度上影响了短期的财报表现。拼多多陈磊表示,在财务数据之外,我们更加看重生态投资带来的长期价值,未来几个季度,拼多多将继续投入“新质供给”“电商西进”等战略,给用户、商家及产业带来更长远的回报。

7分钟前

莎普爱思:股东拟合计减持不超5%公司股份

36氪获悉,莎普爱思公告,股东陈德康持有公司12.39%股份,上海景兴实业投资有限公司持有公司4.7%股份。陈德康计划减持公司股份数量合计不超过758.32万股,即不超过公司总股本的2%。上海景兴计划减持公司股份数量合计不超过1137.48万股,即不超过公司总股本的3%。

7分钟前

永杰新材上交所主板IPO申请获证监会同意注册批复

36氪获悉,证监会下发关于同意永杰新材料股份有限公司首次公开发行股票注册的批复,同意该公司首次公开发行股票的注册申请。根据招股书,该公司拟在上交所主板上市,公司专业从事铝板带箔的研发、生产与销售,产品主要包括铝板带和铝箔两大类。

7分钟前

东方电缆:公司及子公司近期中标合计约40亿元海底电缆项目

36氪获悉,东方电缆公告,公司及全资子公司东方海工院近期收到相关通知书,确认公司及东方海工院联合体为相关项目中标人。其中,直流海底电缆项目中标金额约15.14亿元,交流海底电缆项目中标金额合计约24.72亿元,以上项目合计中标金额约40亿元。同日公告,公司拟以自有资金投资建设东方中央研究院·总部项目,项目总投资金额约为5.54亿元。

7分钟前

本页详细列出关于善元堂SUNOTA的品牌信息,含品牌所属公司介绍,善元堂SUNOTA所处行业的品牌地位及优势。
咨询